Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.

Oncotarget - 18 Oct 2016

Fernandes Maria Sofia, Melo Soraia, Velho Sérgia, Carneiro Patrícia, Carneiro Fátima, Seruca Raquel

Abstract excerpt

Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide. It is often associated with activating mutations in KRAS leading to deregulation of major signaling pathways as the RAS-RAF-MAPK and PI3K-Akt. However, the therapeutic options for CRC patients harboring somatic KRAS mutations are still very limited. It is therefore urgent to unravel novel therapeutic approaches for those patients. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Colorectal Neoplasms

Share to HCT116 Cells

Share to Proto-Oncogene Proteins p21(ras)

Share to RNA Interference

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 27602501
DOI: 10.18632/oncotarget.11843
PMCID: PMC5356572

Genes

KRAS
XIAP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.PMID 27602501Read ↗

Targeted Molecular Therapy of the PI3K PathwaySemantic proximity Read ↗

IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.Semantic proximity Read ↗

BCN057, a Modulator of GSK3β, Induces KRAS G12D Mutant Pancreatic Cancer Cell DeathSemantic proximity Read ↗

Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs.Semantic proximity Read ↗

Brief report: Therapeutic benefit of ISA-2011B in colorectal cancer.Semantic proximity Read ↗

Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.Semantic proximity Read ↗

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.Semantic proximity Read ↗

Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.Semantic proximity Read ↗

Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancerSemantic proximity Read ↗

Targeting the PI3K p110α Isoform Inhibits Medulloblastoma Proliferation, Chemoresistance, and MigrationSemantic proximity Read ↗

PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinomaSemantic proximity Read ↗

Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.